- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
- Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
- Stoke Therapeutics Announces Proposed Public Offering
- Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
- Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
On Thursday, Stoke Therapeutics Inc (STOK:NSQ) closed at 11.65, -28.96% below its 52-week high of 16.40, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.76 |
---|---|
High | 12.27 |
Low | 11.54 |
Bid | 11.20 |
Offer | 16.00 |
Previous close | 11.65 |
Average volume | 1.00m |
---|---|
Shares outstanding | 51.47m |
Free float | 49.08m |
P/E (TTM) | -- |
Market cap | 599.67m USD |
EPS (TTM) | -2.38 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼